Preclinical Services IITRI is a mid-size, non-profit preclinical CRO with strong capabilities in safety and toxicology, inhalation toxicology, infectious disease studies, and cancer biology. Position IITRI as a partner for Sponsors seeking IND enabling studies, translational toxicology programs, and specialized rodent to non-human primate testing with flexible study design and rapid start times.

NCI Partnership As the largest commercial CRO contractor to the National Cancer Institute, IITRI demonstrates established government sponsorship and credibility in cancer therapeutics evaluation. Target pharma/biotech sponsors developing oncology programs that require NCI-aligned preclinical support or infectious disease/biodefense insight.

Infectious Disease Focus With extensive infectious disease expertise and recent activity in collaborations related to SARS-CoV-2, IITRI is well positioned to pursue opportunities in antiviral drug development, vaccine safety/efficacy testing, and biodefense studies—areas of increasing market demand for preclinical validation.

Strategic Partnerships Active engagement in industry conferences and government partnerships (BARDA RRPV) signals readiness for joint initiatives and rapid response collaborations. Leverage these networks to pursue fast-track studies, contract vehicles, and programmatic collaborations with public sector clients.

Operational Scale With over 110,000 sq ft of in-house lab space and a streamlined, single-location setup, IITRI can offer integrated preclinical workflows, efficient study coordination, and consistent quality across rodent, non-rodent, and NHP studies—appealing to sponsors seeking a reliable, end-to-end CRO partner.